AbbVie lately announced the initiation of a Phase 3 clinical trial evaluating the protection and efficacy of its investigational substance, veliparib , when added to carboplatin, a chemotherapy, in women with early-stage, triple-negative breast cancer. The three-arm trial will compare the addition of veliparib plus placebo or carboplatin plus carboplatin to standard neoadjuvant chemotherapy. We expect Phase 3 begins for veliparib in additional cancer types in 2014. AbbVie and its own partner recently initiated a Phase 3 comparative clinical trial made to evaluate the efficacy and safety of ABT-199/GDC-0199, an investigational BCL-2 selective inhibitor, in individuals with relapsed refractory chronic lymphocytic leukemia .Voclosporin hasn’t only demonstrated equivalent efficacy with improvements in safety, but is easy to make use of for clinicians which is a major advantage.’ mentioned Suphamai Bunnapradist, MD, MS, FACP, FASN, Associate Professor of Medicine, UCLA INFIRMARY. ‘A reduced burden of NODAT in patients on voclosporin at the proposed therapeutic dosage was shown in the Phase 2b kidney transplant trial and would symbolize a significant benefit to individuals,’ added Dr.